Wall Street analyst estimates for Plus Therapeutics, Inc. (PSTV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.75 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-13 | $-0.88 | ||
| 2026-05-15 | $-1.05 | $-0.95 | -10.5% |
| 2026-03-12 | $-0.83 | $-0.80 | -4.2% |
| 2025-10-30 | $-1.00 | $-0.50 | -100.0% |
| 2025-08-14 | $-0.25 | $-2.25 | +88.9% |
| 2025-05-30 | $-14.00 | $-4.25 | -229.4% |
| 2025-03-27 | $-16.75 | $-12.42 | -34.9% |
| 2024-11-14 | $-11.50 | $-11.50 | +0.0% |
Valuation Ratios
| Price / Book | 4.80 |
| EV / EBITDA | -1.74 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $6.4M | $3.0M | $7.0M | $303000 | 0 | $224000 | $4.9M | $5.8M | $5.2M |
| Cost of Revenue | $2.7M | $1.3M | $1.1M | 0 | $2.7M | $66000 | $712000 | $9.7M | $852000 | $445000 |
| Gross Profit | $8.7M | $5.1M | $1.8M | $7.0M | -$2.4M | -$66000 | -$488000 | -$4.8M | $5.0M | $4.8M |
| Research & Development | $16.2M | $13.4M | $5.5M | $5.4M | $3.5M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M |
| Selling, General & Admin | $12.2M | $11.2M | $6.2M | $5.3M | $6.4M | $6.9M | $9.5M | $8.5M | $9.9M | $12.1M |
| Operating Expenses | $28.4M | $25.8M | $10.8M | $10.7M | $7.2M | $12.4M | $19.2M | $8.5M | $19.7M | $20.1M |
| Operating Income | -$19.7M | -$20.7M | -$8.8M | -$3.7M | -$9.6M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| EBITDA | -$18.3M | -$18.5M | -$6.6M | -$532000 | -$8.4M | -$12.0M | -$18.9M | -$12.3M | -$8.4M | -$18.3M |
| Interest Expense | $2.6M | $2.0M | $1.9M | $1.9M | $1.1M | $932000 | $711000 | $395000 | $3.7M | $3.6M |
| Pre-tax Income | -$22.0M | -$22.7M | -$8.9M | -$3.3M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$22.0M | -$22.7M | -$12.6M | -$10.9M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| EPS | $-240000000.00 | $-131345500.00 | $-32617500.00 | $-3101250.00 | $-697500.00 | $-444500.00 | $-288750.00 | $-106000.00 | $-48.75 | $-7.19 |
| EPS (Diluted) | $-240000000.00 | $-131345500.00 | $-32617500.00 | $-3452500.00 | $-697500.00 | $-444500.00 | $-288750.00 | $-106000.00 | $-58.50 | $-7.19 |
| Shares Outstanding (Diluted) | $692 | $17 | $0 | $4 | $12 | $32 | $70 | $126 | $308030 | $3.1M |
Price
| Price | $3.87 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADTX · BXRXQ · EDSA · MTVA · PHIO · RKTO
Explore sector: Healthcare · Biotechnology
More sections of PSTV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks